The following characteristics were identified: median age of 66years (range 3690years), male predominance (81%; 192/237), advanced clinical stage (III) in the majority of patients (87%; 169/195), more than two extranodal sites (37%; 66/180), advanced International Prognostic Index(32)score (54%; 96/179), and bone marrow involvement (52%; 94/182). 24.3%, and 2.5 13.0%, respectively) and intermediate MCL (mean 75.7 31.4%, 30.8 33.3%, 21.0 57.4%, and 4.8 16.5%, respectively). Significantly different levels of Ki67 and p21WAF/Cip1were only acknowledged between intermediate and aggressive (P<0.05 andP<0.0001, respectively), whereas those of CCND1 and p53 were only between classical and intermediate (P<0.0001 andP<0.05, respectively). There were no significant differences in p27Kip1among the three groups. The subsequent discriminant analysis with impartial prognostic factors clearly demonstrated that this morphological development of MCL occurs in parallel with increased labeling index of CCND1 and Ki67. The diagnosis of intermediate MCL thus proved to be of major significance and should enable the design of more tailored therapies. Mantle cell lymphoma (MCL) is usually characterized by a nodular (N) or diffuse (D) proliferation of atypical small to mediumsized Blymphoid cells. The t(11;14)(q13;q32) resulting in overexpression of cyclin D1 (CCND1) is known as the genetic hallmark.(1,2)Although it is generally accepted that this median overall survival is 35 years, MCL patients show a broad spectrum of clinical behavior(3,4,5,6)and a variety of morphological forms.(3,4,5,6,7)This suggests that MCL consists of different states of CCND1positive Bcell neoplasm. The World Health Business (WHO) classification defines two main morphological subtypes of MCL: classical and aggressive (blastoid and pleomorphic variant).(8,9)MCL with the aggressive form is considered one of the worst varieties of nonhodgkin lymphoma (NHL) with a median overall survival time of less than 2 years.(3,4,5,6)On the other hand, some MCL patients with the classical form show excellent prognosis.(6,10)Interestingly, several investigators have noted that in some MCL cases the aggressive and classical forms could not be distinguished because morphologically the two Rabbit Polyclonal to EMR2 features involved the same site.(5,6,11)In fact, we have often encountered this type of MCL as the result of a careful examination of every tissue and we have named this feature MCL with focal aggressive form (intermediate MCL). As launched in several studies, MCL subsequently evolves into aggressive MCL with a clonal link at the genetic level,(11,12,13,14)and one retrospective analysis revealed that blastoid transformation of MCL was found to occur in 32% of living cases and in 70% of autopsied cases.(15)These findings may represent evidence of the existence and frequency of transformation in MCL. For basic MCL cell proliferation, the following three growth patterns have been established: mantle zone (MZ), vaguely N, and D. A proliferation of MZ MCL cells surrounding residual germinal centers, that is, the MZ pattern, is found in 1520% of all cases(7)and is possibly the most characteristic growth pattern of MCL, and it has been suggested that it generally represents the initial component of MCL.(12)Indeed, MCL patients with MZ pattern have been reported to have a long survival(16,17)whereas patients with the diffuse pattern have a much worse prognosis than the cases consisting predominantly of N components.(4,6)But the correlation between growth pattern and prognosis remains controversial as does the classification of morphological subtypes. To determine molecular pathogenesis as part of the process of morphological transition in MCL, cell cycle regulatory molecules may play an important role. The cell cycle transition from G1to S phase is regulated by CCND1cyclindependent kinase (CDK) 4 and 6 complexes, which phosphorylate the retinoblastoma protein, and CCND1 participates in the cell cycle by binding to CDK4/6.(18,19)Although some cell cycle proteins, such as p21WAF1,(20,21,22)p27KIP1,(20,23,24,25)and p53,(26,27,28)are thought to be involved in the pathogenesis of MCL, the CCND1 protein expression levels and the correlation with morphological subtypes have not been sufficiently investigated yet. From a practical point of view, we posed some questions. One is whether the new morphological subtype intermediate MCL is useful for an independent morphological differentiation of the classical and aggressive forms. The other question is usually UNC0321 whether there are different subtypes of MCL in the cell cycle regulatory molecules including CCND1 and proliferative.The prognosis of intermediate MCL was between the two. p53 were only between classical and intermediate (P<0.0001 andP<0.05, respectively). There were no significant differences in p27Kip1among the three groups. The subsequent discriminant analysis with impartial prognostic factors clearly demonstrated that this morphological development of MCL occurs in parallel with increased labeling index of CCND1 and Ki67. The diagnosis of intermediate MCL thus proved to be of major significance and should enable the design of more tailored therapies. Mantle cell lymphoma (MCL) is usually characterized by a nodular (N) or diffuse (D) proliferation of atypical small to mediumsized Blymphoid cells. The t(11;14)(q13;q32) resulting in overexpression of cyclin D1 (CCND1) is known as the genetic hallmark.(1,2)Although it is generally accepted that this median overall survival is 35 years, MCL patients show a broad spectrum of clinical behavior(3,4,5,6)and a variety of morphological forms.(3,4,5,6,7)This suggests that MCL consists of different states of CCND1positive Bcell neoplasm. The World Health Business (WHO) classification defines two main morphological subtypes of MCL: classical and aggressive (blastoid and pleomorphic variant).(8,9)MCL with the aggressive form is considered one of the worst varieties of nonhodgkin lymphoma (NHL) with a median overall survival time of less than 2 years.(3,4,5,6)On the other hand, some MCL patients with the classical form show excellent prognosis.(6,10)Interestingly, several investigators have noted that in some MCL cases the aggressive and classical forms could not be distinguished because morphologically the two features involved the same site.(5,6,11)In fact, we have often encountered this type of MCL as the result of a careful examination of every tissue and we have named this feature MCL with focal aggressive form (intermediate MCL). As launched in several studies, MCL subsequently evolves into aggressive MCL with a clonal link at the genetic level,(11,12,13,14)and one retrospective analysis revealed that blastoid transformation of MCL was found to occur in 32% of living cases and in 70% of autopsied cases.(15)These findings may represent evidence of the existence and frequency of transformation in MCL. For basic MCL cell proliferation, the following three growth patterns have been established: mantle zone (MZ), vaguely N, and D. A proliferation of MZ MCL cells surrounding residual germinal centers, that is, the MZ pattern, is found in 1520% of all cases(7)and is possibly the most characteristic growth pattern of MCL, and it has been suggested that it generally represents the initial component of MCL.(12)Indeed, MCL patients with MZ pattern have been reported to have a long survival(16,17)whereas patients with the diffuse pattern have a much worse prognosis than the cases consisting predominantly of N components.(4,6)But the correlation between growth pattern and prognosis remains controversial as does the classification of morphological subtypes. To determine molecular pathogenesis as part of the process of morphological transition in MCL, cell cycle regulatory molecules may play an important role. The cell cycle transition from G1to S phase is regulated by CCND1cyclindependent kinase (CDK) 4 and 6 complexes, which phosphorylate the retinoblastoma protein, and CCND1 participates in the cell cycle by binding to CDK4/6.(18,19)Although some cell cycle proteins, such as p21WAF1,(20,21,22)p27KIP1,(20,23,24,25)and p53,(26,27,28)are thought to be involved in the pathogenesis of MCL, the CCND1 protein expression levels and the correlation with morphological subtypes have not been sufficiently investigated yet. From a practical point of view, we posed some questions. One is whether the new morphological subtype intermediate MCL is useful for an independent morphological differentiation of the classical and aggressive forms. The other question is whether there are different subtypes of MCL in the cell cycle regulatory.Comparison of the expression levels of CCND1 and Ki67 in the subtypes according to this flowchart demonstrated that the levels of both CCND1 and Ki67 in intermediate MCL tended to be midway between those in classical MCL and aggressive MCL (Fig.3c). == UNC0321 Discussion == Although MCL clinically consists of a wide variety of CCND1positive neoplasms, there has, until now, been no systematic blueprint for the morphological evolution of MCL tumor. between classical and intermediate (P<0.0001 andP<0.05, respectively). There were no significant differences in p27Kip1among the three groups. The subsequent discriminant analysis with independent prognostic factors clearly demonstrated that the morphological evolution of MCL occurs in parallel with increased labeling index of CCND1 and Ki67. The diagnosis of intermediate MCL thus proved to be of major significance and should enable the design of more tailored therapies. Mantle cell lymphoma (MCL) is characterized by a nodular (N) or diffuse (D) proliferation of atypical small to mediumsized Blymphoid cells. The t(11;14)(q13;q32) resulting in overexpression of cyclin D1 (CCND1) is known as the genetic hallmark.(1,2)Although it is generally accepted that the median overall survival is 35 years, MCL patients show a broad spectrum of clinical behavior(3,4,5,6)and a variety of morphological forms.(3,4,5,6,7)This suggests that MCL consists of different states of CCND1positive Bcell neoplasm. The World Health Organization (WHO) classification defines two main morphological subtypes of MCL: classical and aggressive (blastoid and pleomorphic variant).(8,9)MCL with the aggressive form is considered one of the worst varieties of nonhodgkin lymphoma (NHL) with a median overall survival time of less UNC0321 than 2 years.(3,4,5,6)On the other hand, some MCL patients with the classical form show excellent prognosis.(6,10)Interestingly, several investigators have noted that in some MCL cases the aggressive and classical forms could not be distinguished because morphologically the two features involved the same site.(5,6,11)In fact, we have often encountered this type of MCL as the result of a careful examination of every tissue and we have named this feature MCL with focal aggressive form (intermediate MCL). As introduced in several studies, MCL subsequently develops into aggressive MCL with a clonal link at the genetic level,(11,12,13,14)and one retrospective analysis revealed that blastoid transformation of MCL was found to occur in 32% of living cases and in 70% of autopsied cases.(15)These findings may represent evidence of the existence and frequency of transformation in MCL. For basic MCL cell proliferation, the following three growth patterns have been established: mantle zone (MZ), vaguely N, and D. A proliferation of MZ MCL cells surrounding residual germinal centers, that is, the MZ pattern, is found in 1520% of all cases(7)and is possibly the most characteristic growth pattern of MCL, and it has been suggested that it generally represents the initial component of MCL.(12)Indeed, MCL patients with MZ pattern have been reported to have a long survival(16,17)whereas patients with the diffuse pattern have a much worse prognosis than the cases consisting predominantly of N components.(4,6)But the correlation between growth pattern and prognosis remains controversial as does the classification of morphological subtypes. To determine molecular pathogenesis as part of the process of morphological transition in MCL, cell cycle regulatory molecules may play an important role. The cell cycle transition from G1to S phase is regulated by CCND1cyclindependent kinase (CDK) 4 and 6 complexes, which phosphorylate the retinoblastoma protein, and CCND1 participates in the cell cycle by binding to CDK4/6.(18,19)Although some cell cycle proteins, such as p21WAF1,(20,21,22)p27KIP1,(20,23,24,25)and p53,(26,27,28)are thought to be involved in the pathogenesis of MCL, the CCND1 protein expression levels and the correlation with morphological subtypes have not been.The following characteristics were identified: median age of 66years (range 3690years), male predominance (81%; 192/237), advanced clinical stage (III) in the majority of patients (87%; 169/195), more than two extranodal sites (37%; 66/180), advanced International Prognostic Index(32)score (54%; 96/179), and bone marrow involvement (52%; 94/182). 24.3%, and 2.5 13.0%, respectively) and intermediate MCL (mean 75.7 31.4%, 30.8 33.3%, 21.0 57.4%, and 4.8 16.5%, respectively). Significantly different levels of Ki67 and p21WAF/Cip1were only acknowledged between intermediate and aggressive (P<0.05 andP<0.0001, respectively), whereas those of CCND1 and p53 were only between classical and intermediate (P<0.0001 andP<0.05, respectively). There ISX-9 were no significant differences in p27Kip1among the three groups. The subsequent discriminant analysis with impartial prognostic factors clearly demonstrated that this morphological development of MCL occurs in parallel with increased labeling index of CCND1 and Ki67. The diagnosis of intermediate MCL thus proved to be of major significance and should enable the design of more tailored therapies. Mantle cell lymphoma (MCL) is usually characterized by a nodular (N) or diffuse (D) proliferation of atypical small to mediumsized Blymphoid cells. The t(11;14)(q13;q32) resulting in overexpression of cyclin D1 (CCND1) is known as the genetic hallmark.(1,2)Although it is generally accepted that this median overall survival is 35 years, MCL patients show a broad spectrum of clinical behavior(3,4,5,6)and a variety of morphological forms.(3,4,5,6,7)This suggests that MCL consists of different states of CCND1positive Bcell neoplasm. The World Health Business (WHO) classification defines two main morphological subtypes of MCL: classical and aggressive (blastoid and pleomorphic variant).(8,9)MCL with the aggressive form is considered one of the worst varieties of nonhodgkin lymphoma (NHL) with a median overall survival time of less than 2 years.(3,4,5,6)On the other hand, some MCL patients with the classical form show excellent prognosis.(6,10)Interestingly, several investigators have noted that in some MCL cases the aggressive and classical forms could not be distinguished because morphologically the two features involved the same site.(5,6,11)In fact, we have often encountered this type of MCL as the result of a careful examination of every tissue and we have named this feature MCL with focal aggressive form (intermediate MCL). As launched in several studies, MCL subsequently evolves into aggressive MCL with a clonal link at the genetic level,(11,12,13,14)and one retrospective analysis revealed that blastoid transformation of MCL was found to occur in 32% of living cases and in 70% of autopsied cases.(15)These findings may represent evidence of the existence and frequency of transformation in MCL. For basic MCL cell proliferation, the following three growth patterns have been established: mantle zone (MZ), vaguely N, and D. A proliferation of MZ MCL cells surrounding residual germinal centers, that is, the MZ pattern, is found in 1520% of all cases(7)and is possibly the most characteristic growth pattern of MCL, and it has been suggested that it generally represents the initial component of MCL.(12)Indeed, MCL patients with MZ pattern have been reported to have a long survival(16,17)whereas patients with the diffuse pattern have a much worse prognosis than the cases consisting predominantly of N components.(4,6)But the correlation AURKB between growth pattern and prognosis remains controversial as does the classification of morphological subtypes. To determine molecular pathogenesis as part of the process of morphological transition in MCL, cell cycle regulatory molecules may play an important role. The cell cycle transition from G1to S phase is regulated by CCND1cyclindependent kinase (CDK) 4 and 6 complexes, which phosphorylate the retinoblastoma protein, and CCND1 participates in the cell cycle by binding to CDK4/6.(18,19)Although some cell cycle proteins, such as p21WAF1,(20,21,22)p27KIP1,(20,23,24,25)and p53,(26,27,28)are thought to be involved in the pathogenesis of MCL, the CCND1 protein expression levels and the correlation with morphological subtypes have not been sufficiently investigated yet. From a practical point of view, we posed some questions. One is whether the new morphological subtype intermediate MCL is useful for an independent morphological differentiation of the classical and aggressive forms. The other question is usually whether there are different subtypes of MCL in the cell cycle regulatory molecules including CCND1 and proliferative.The prognosis of intermediate MCL was between the two. p53 were only between classical and intermediate (P<0.0001 andP<0.05, respectively). There were no significant differences in p27Kip1among the three groups. The subsequent discriminant analysis with impartial prognostic factors clearly demonstrated that this morphological development of MCL occurs in parallel with increased labeling index of CCND1 and Ki67. The diagnosis of intermediate MCL thus proved to be of major significance and should enable the design of more tailored therapies. Mantle cell lymphoma (MCL) is usually characterized by a nodular (N) or diffuse (D) proliferation of atypical small to mediumsized Blymphoid cells. The t(11;14)(q13;q32) resulting in overexpression of cyclin D1 (CCND1) is known as the genetic hallmark.(1,2)Although it is generally accepted that this median overall survival is 35 years, MCL patients show a broad spectrum of clinical behavior(3,4,5,6)and a variety of morphological forms.(3,4,5,6,7)This suggests that MCL consists of different states of CCND1positive Bcell neoplasm. The World Health Business (WHO) classification defines two main morphological subtypes of MCL: classical and aggressive (blastoid and pleomorphic variant).(8,9)MCL with the aggressive form is considered one of the worst varieties of nonhodgkin lymphoma (NHL) with a median overall survival time of less than 2 years.(3,4,5,6)On the other hand, some MCL patients with the classical form show excellent prognosis.(6,10)Interestingly, several investigators have noted that in some MCL cases the aggressive and classical forms could not be distinguished because morphologically the two features involved the same site.(5,6,11)In fact, we have often encountered this type of MCL as the result of a careful examination of every tissue and we have named this feature MCL with focal aggressive form (intermediate MCL). As launched in several studies, MCL subsequently evolves into aggressive MCL with a clonal link at the genetic level,(11,12,13,14)and one retrospective analysis revealed that blastoid transformation of MCL was found to occur in 32% of living cases and in 70% of autopsied cases.(15)These findings may represent evidence of the existence and frequency of transformation in MCL. For basic MCL cell proliferation, the following three growth patterns have been established: mantle zone (MZ), vaguely N, and D. A proliferation of MZ MCL cells surrounding residual germinal centers, that is, the MZ pattern, is found in 1520% of all cases(7)and is possibly the most characteristic growth pattern of MCL, and it has been suggested that it generally represents the initial component of MCL.(12)Indeed, MCL patients with MZ pattern have been reported to have a long survival(16,17)whereas patients with the diffuse pattern have a much worse prognosis than the cases consisting predominantly of N components.(4,6)But the correlation between growth pattern and prognosis remains controversial as does the classification of morphological subtypes. To determine molecular pathogenesis as part of the process of morphological transition in MCL, cell cycle regulatory molecules may play an important role. The cell cycle transition from G1to S phase is regulated by CCND1cyclindependent kinase (CDK) 4 and 6 complexes, which phosphorylate the retinoblastoma protein, and CCND1 participates in the cell cycle by binding to CDK4/6.(18,19)Although some cell cycle proteins, such as p21WAF1,(20,21,22)p27KIP1,(20,23,24,25)and p53,(26,27,28)are thought to be involved in the pathogenesis of MCL, the CCND1 protein expression levels and the correlation with morphological subtypes have not been sufficiently investigated yet. From a practical point of view, we posed some questions. One is whether the new morphological subtype intermediate MCL is useful for an independent morphological differentiation of the classical and aggressive forms. The other question is whether there are different subtypes of MCL in the cell cycle regulatory.Comparison of the expression levels of CCND1 and Ki67 in the subtypes according to this flowchart demonstrated that the levels of both CCND1 and Ki67 in intermediate MCL tended to be midway between those in classical MCL and aggressive MCL (Fig.3c). == Discussion == Although MCL clinically consists of a wide variety of CCND1positive neoplasms, there has, until now, been no systematic blueprint for the morphological evolution of MCL tumor. between classical and intermediate (P<0.0001 andP<0.05, respectively). There were no significant differences in p27Kip1among the three groups. The subsequent discriminant analysis with independent prognostic factors clearly demonstrated that the morphological evolution of MCL occurs in parallel with increased labeling index of CCND1 and Ki67. The diagnosis of intermediate MCL thus proved to be of major significance and should enable the design of more tailored therapies. Mantle cell lymphoma (MCL) is characterized by a nodular (N) or diffuse (D) proliferation of atypical small to mediumsized Blymphoid cells. The t(11;14)(q13;q32) resulting in overexpression of cyclin D1 (CCND1) is known as the genetic hallmark.(1,2)Although it is generally accepted that the median overall survival is 35 years, MCL patients show a broad spectrum of clinical behavior(3,4,5,6)and a variety of morphological forms.(3,4,5,6,7)This suggests that MCL consists of different states of CCND1positive Bcell neoplasm. The World Health Organization (WHO) classification defines two main morphological subtypes of MCL: classical and aggressive (blastoid and pleomorphic variant).(8,9)MCL with the aggressive form is considered one of the worst varieties of nonhodgkin lymphoma (NHL) with a median overall survival time of less than 2 years.(3,4,5,6)On the other hand, some MCL patients with the classical form show excellent prognosis.(6,10)Interestingly, several investigators have noted that in some MCL cases the aggressive and classical forms could not ISX-9 be distinguished because morphologically the two features involved the same site.(5,6,11)In fact, we have often encountered this type of MCL as the result of a careful examination of every tissue and we have named this feature MCL with focal aggressive form (intermediate MCL). As introduced in several studies, MCL subsequently develops into aggressive MCL with a clonal link at the genetic level,(11,12,13,14)and one retrospective analysis revealed that blastoid transformation of MCL was found to occur in 32% of living cases and in 70% of autopsied cases.(15)These findings may represent evidence of the existence and frequency of transformation in MCL. For basic MCL cell proliferation, the following three growth patterns have been established: mantle zone (MZ), vaguely N, and D. A proliferation of MZ MCL cells surrounding residual germinal centers, that is, the MZ pattern, is found in 1520% of all cases(7)and is possibly the most characteristic growth pattern of MCL, and it has been suggested that it generally represents the initial component of MCL.(12)Indeed, MCL patients with MZ pattern have been reported to have a long survival(16,17)whereas patients with the diffuse pattern have a much worse prognosis than the cases consisting predominantly of N components.(4,6)But the correlation between growth pattern and prognosis remains controversial as does the classification of morphological subtypes. To determine molecular pathogenesis as part of the process of morphological transition in MCL, cell cycle regulatory molecules may play an important role. The cell cycle transition from G1to S phase is regulated by CCND1cyclindependent kinase (CDK) 4 and 6 complexes, which phosphorylate the retinoblastoma protein, and CCND1 participates in the cell cycle by binding to CDK4/6.(18,19)Although some cell ISX-9 cycle proteins, such as p21WAF1,(20,21,22)p27KIP1,(20,23,24,25)and p53,(26,27,28)are thought to be involved in the pathogenesis of MCL, the CCND1 protein expression levels and the correlation with morphological subtypes have not been.